Title
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Permalink
https://escholarship.org/uc/item/5jp571t9

Journal
Critical Care, 21(1)

ISSN
1364-8535

Authors
Khan, A
Benthin, C
Zeno, B
et al.

Publication Date
2017-09-07

DOI
10.1186/s13054-017-1823-x

Peer reviewed
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Akram Khan¹, Cody Benthin¹, Brian Zeno², Timothy E. Albertson³, John Boyd⁴, Jason D. Christie⁵, Richard Hall⁶, Germain Poirier⁷, Juan J. Ronco⁸, Mark Tidswell⁹, Kelly Hardes¹⁰, William M. Powley¹¹, Tracey J. Wright¹¹, Sarah K. Siederer¹¹, David A. Fairman¹¹, David A. Lipson⁵,¹², Andrew I. Bayliffe¹¹, and Aili L. Lazaar⁵,¹²*†

Abstract

**Background:** Renin-angiotensin system (RAS) signaling and angiotensin-converting enzyme 2 (ACE2) have been implicated in the pathogenesis of acute respiratory distress syndrome (ARDS). We postulated that repleting ACE2 using GSK2586881, a recombinant form of human angiotensin-converting enzyme 2 (rhACE2), could attenuate acute lung injury.

**Methods:** We conducted a two-part phase II trial comprising an open-label intrapatient dose escalation and a randomized, double-blind, placebo-controlled phase in ten intensive care units in North America. Patients were between the ages of 18 and 80 years, had an American-European Consensus Criteria consensus diagnosis of ARDS, and had been mechanically ventilated for less than 72 h. In part A, open-label GSK2586881 was administered at doses from 0.1 mg/kg to 0.8 mg/kg to assess safety, pharmacokinetics, and pharmacodynamics. Following review of data from part A, a randomized, double-blind, placebo-controlled investigation of twice-daily doses of GSK2586881 (0.4 mg/kg) for 3 days was conducted (part B). Biomarkers, physiological assessments, and clinical endpoints were collected over the dosing period and during follow-up.

**Results:** Dose escalation in part A was well-tolerated without clinically significant hemodynamic changes. Part B was terminated after 39 of the planned 60 patients following a planned futility analysis. Angiotensin II levels decreased rapidly following infusion of GSK2586881, whereas angiotensin-(1–7) and angiotensin-(1–5) levels increased and remained elevated for 48 h. Surfactant protein D concentrations were increased, whereas there was a trend for a decrease in interleukin-6 concentrations in rhACE2-treated subjects compared with placebo. No significant differences were noted in ratio of partial pressure of arterial oxygen to fraction of inspired oxygen, oxygenation index, or Sequential Organ Failure Assessment score.

**Conclusions:** GSK2586881 was well-tolerated in patients with ARDS, and the rapid modulation of RAS peptides suggests target engagement, although the study was not powered to detect changes in acute physiology or clinical outcomes.

**Trial registration:** ClinicalTrials.gov, NCT01597635. Registered on 26 January 2012.

**Keywords:** Angiotensin-converting enzyme 2, Acute lung injury, Respiratory distress syndrome, Adult, Acute respiratory failure, Renin-angiotensin system, Humans, Interleukin-6
Background

The renin-angiotensin system (RAS) regulates vascular tone and fluid-electrolyte homeostasis in a wide range of tissues [1–4]. Angiotensin II (Ang II), formed by the activity of angiotensin-converting enzyme (ACE) on angiotensin I (Ang I), is the key effector peptide of the RAS and, via the angiotensin type I receptor (AT1R), mediates physiological effects, including vasoconstriction, inflammation, apoptosis, capillary leak, and fibroproliferation [5–8]. ACE2 is a membrane-bound carboxypeptidase that hydrolyzes Ang II to the heptapeptide Angiotensin-(1–7) (Ang 1–7). ACE2 regulates RAS signaling, both directly by reducing Ang II/AT1R signaling and indirectly by activating the counterregulatory Ang 1–7/Mas receptor pathway [9–12].

RAS signaling and ACE2 have been implicated in the pathogenesis of acute respiratory distress syndrome (ARDS). Mice deficient in ACE2 developed severe acute lung injury (ALI) following challenge with a variety of insults [13, 14], which improved on repletion with recombinant ACE2 [15]. The importance of ACE/Ang II signaling in human disease is suggested by increased levels of ACE and Ang II in patients with ARDS and patients with sepsis [16–19], and it is further underlined by genetic studies of an insertion/deletion (I/D) polymorphism within the ACE gene, with the D allele conferring higher ACE and Ang II levels in tissue and serum [20]. A number of studies and meta-analyses [20–23] suggest an association between the ACE D allele and mortality in ARDS cohorts.

A recombinant version of the catalytic ectodomain of human ACE2 (rhACE2, GSK2586881) attenuated arterial hypoxemia in a piglet model of lipopolysaccharide-induced ALI [24] and was well-tolerated when administered to healthy human volunteers [25]. We postulated that the addition of exogenous ACE2 in patients with ARDS could attenuate lung injury without compromising systemic hemodynamics. We report the results of a prospective, placebo-controlled trial of GSK2586881 in mechanically ventilated patients with ARDS. The aim of the trial was to establish preliminary safety, pharmacokinetics (PK), and pharmacodynamics (PD) in critically ill patients and to explore the effects of GSK2586881 on relevant physiological measures of ARDS.

Methods

Study design and data collection

Between September 2012 and October 2014, we conducted a phase II study in ten intensive care units in the United States and Canada (GSK protocol ACE114622, ClinicalTrials.gov identifier NCT01597635). After institutional review board approval was obtained at each institution, written informed consent was obtained from each patient or the patient's legally authorized surrogate prior to conduct of study-specific procedures. The study was conducted in accordance with International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice and all applicable subject privacy requirements, as well as the ethical principles outlined in the 2013 Declaration of Helsinki [26].

The study was designed in two parts. Part A was an open-label, within-subject dose escalation of GSK2586881 in hemodynamically stable patients with ARDS. The primary objective of part A was to ascertain whether ACE2 would adversely impact systemic hemodynamics in critically ill patients. Four consecutive intravenous (IV) doses of GSK2586881 (0.1 mg/kg, 0.2 mg/kg, 0.4 mg/kg, and 0.8 mg/kg) were administered to each subject at baseline and intervals of 2, 4, and 18 h, respectively. Hemodynamic assessments were carried out after each infusion and prior to escalating to the next higher dose. The 0.1 mg/kg was chosen as the starting dose because it was anticipated that this dose would produce a minimal pharmacological effect, based on the limited preclinical data derived from the piglet model and from the first-in-human study. On the basis of modelling predictions and using a conservative total dose of 0.7 mg/kg on the first day, this dose escalation strategy was not expected to result in drug accumulation. The highest dose (0.8 mg/kg) to be administered on day 2 of part A was selected to provide generous safety margins that were based on preclinical findings, because it was believed that doses < 0.8 mg/kg would prove efficacious in lowering Ang II levels.

Part B was a double-blind (sponsor unblinded) investigation comparing 3 days of twice-daily infusions of 0.4 mg/kg GSK2586881 with matched placebo. The sponsor was unblinded to allow for in-stream analysis of safety data only. The exploratory statistical decision-making framework related to PD, physiological, and clinical endpoints, as well as all outputs and reporting and analysis plans, were all defined, prepared, and approved prior to unblinding of any part B data. Subjects were randomized using a 1:1 allocation. Dose selection was based on modeling of PK and PD profiles (e.g., Ang II levels) of healthy subjects dosed with IV GSK2586881 in previous trials [25] and dose-response/duration relationships established in large animal ARDS models [24]. The primary objective of part B was to assess the safety and tolerability of GSK2256881, including adverse event (AE) reporting, clinical laboratory tests and immunogenicity, vital signs, electrocardiograms, and physical examinations. Secondary endpoints included an assessment of PK, PD, and biomarkers (details described in Additional file 1). Physiological and clinical endpoints were considered exploratory. On the basis of the anticipated pharmacology of the compound, 3 days of dosing was felt to be adequate to
define the initial safety of the drug in critically ill patients, its PK, and to show a PD effect.

**Inclusion and exclusion criteria**

Eligible patients included male or female subjects 18–80 years of age who were diagnosed with ARDS within 48 h of randomization that was associated with infection, sepsis, pneumonia, aspiration, or similar disease, based on the American-European Consensus Criteria [27]. Subjects were enrolled if hemodynamically stable in the 4–6 h preceding the initiation of study treatment, with stable pressor requirements, on mechanical ventilation for <72 h before dosing began, and were managed with low tidal volume mechanical ventilation. Full eligibility criteria are described in Additional file 1.

**Statistical methods**

Part B of the study was designed to randomize 60 subjects, with planned interim analyses after approximately half the subjects had completed 7 days of follow-up. In the original protocol, the interim analysis in part B was planned to allow for a sample size reestimation based on Ang II and Ang 1–5 responses. Following a planned review of data from five subjects in part A in which the effects of GSK2586881 on RAS peptides were clearer than expected, the protocol was amended to switch the objective of the part B interim analysis from confirmation of pharmacology (e.g., plasma Ang II and Ang 1–5) to a futility analysis assessing the impact on ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (PaO₂/FiO₂) as a surrogate for potential beneficial physiological activity. This change was implemented prior to reviewing/unblinding of any data from part B.

A Bayesian statistical framework was employed, which allows quantitative statements of statistical significance to be constructed from posterior distributions [28]. This approach was considered most appropriate for a study where the potential treatment effects of the investigational medicine were less well defined. Additional details are provided in Additional file 1.

**Results**

Forty-six subjects were enrolled, of whom 44 (5 in part A and 39 in part B) received at least one dose of study medication (Fig. 1). In part B, 16 of 20 patients on placebo and 16 of 19 patients receiving GSK2586881 received all 6 planned doses. Baseline characteristics and demographics are shown in Table 1 and Additional file 1: Table S1. At baseline, subjects who received GSK2586881 in part B had higher Sequential Organ Failure Assessment (SOFA) scores and lower PaO₂/FiO₂ ratios than patients receiving placebo (Table 1); other characteristics were similar between groups. The study was terminated after randomizing 39 of the planned 60 patients in part B, following the planned futility analysis.

**Safety and tolerability**

In part A, no clinically significant changes in hemodynamic parameters were observed. The most commonly reported AE was atrial fibrillation (Additional file 1: Table S2); no AEs were considered drug-related. Three subjects who died had ten serious adverse events (SAEs). None of the SAEs was considered drug-related, with the exception of one...
subject who developed acute renal failure 4 days after the last dose of study drug (Additional file 1: Table S5).

In part B, 29 (75%) subjects experienced an AE (Additional file 1: Table S3). Hypernatremia, rash, dysphagia, and pneumonia occurred more frequently in subjects receiving GSK2586881. Three subjects in each treatment group had AEs that were considered by the investigator to be possibly related to study drug (Additional file 1: Table S4). Four (20%) subjects on placebo experienced six SAEs, and three (16%) subjects treated with GSK2586881 experienced four SAEs (Additional file 1: Table S5). Three subjects experienced fatal AEs, two in the placebo group (multiorgan failure and septic shock) and one in the GSK2586881 group (anastomotic dehiscence following lobectomy). None of the fatal events was considered related to study treatment. One patient on placebo was withdrawn because of increased hepatic transaminases. There were ten deaths in part B, including six (30%) subjects on placebo and four (21%) subjects who received GSK2586881. A full listing of AEs is included in Additional file 1: Tables S2–S5.

**Pharmacodynamics and biomarkers**

**RAS biomarkers**

Baseline concentrations of plasma Ang II varied considerably between subjects (Additional file 1: Figure S1). In patients who received GSK2586881, Ang II levels decreased dramatically after infusion and were sustained for up to 5 days (Fig. 2a). The nadir of Ang II was observed within the first 12 h and as early as 30 minutes

---

Table 1 Demographic and baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Part A</th>
<th>Part B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>rhACE2 0.1 -&gt; 0.2 -&gt; 0.4 -&gt; 0.8 mg/kg</td>
<td>Placebo BID</td>
</tr>
<tr>
<td>Number of subjects planned</td>
<td>5</td>
<td>30</td>
</tr>
<tr>
<td>All subjects population</td>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td>Age, years, mean (SD)</td>
<td>50.8 (17.04)</td>
<td>50.5 (15.44)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td>Female 2 (40)</td>
<td>7 (35)</td>
</tr>
<tr>
<td></td>
<td>Male 3 (60)</td>
<td>13 (65)</td>
</tr>
<tr>
<td>BMI, kg/m², mean (SD)</td>
<td>31.4 (5.43)</td>
<td>29.59 (6.896)</td>
</tr>
<tr>
<td>Time since ARDS, h</td>
<td>17.8 (10.8)</td>
<td>26.899 (13.82)</td>
</tr>
<tr>
<td>Glasgow Coma Scale</td>
<td>6.6 (2.51)</td>
<td>8.2 (4.47)</td>
</tr>
<tr>
<td>SOFA score</td>
<td>10.8 (2.49)</td>
<td>7.8 (2.79)</td>
</tr>
<tr>
<td>PaO₂/FiO₂, geometric mean (SD on logarithmic scale)</td>
<td>140.3 (0.468)</td>
<td>160.5 (0.523)</td>
</tr>
<tr>
<td>PEEP, cmH₂O</td>
<td>14.0 (0.196)</td>
<td>10.4 (0.438)</td>
</tr>
<tr>
<td>Ang II, pg/ml</td>
<td>26.5 (0.513)</td>
<td>11.4 (1.834)</td>
</tr>
</tbody>
</table>

Abbreviations: Ang Angiotensin, ARDS Acute respiratory distress syndrome, BMI Body mass index, PaO₂/FiO₂ Ratio of partial pressure of arterial oxygen to fraction of inspired oxygen, PEEP Positive end-expiratory pressure, rhACE2 Recombinant human angiotensin-converting enzyme 2, SOFA Sequential Organ Failure Assessment

---

Fig. 2 Change from baseline in plasma concentrations of angiotensin II (Ang II) (a), Ang 1–7 (b), and Ang 1–5 (c) following treatment with placebo or GSK2586881 (recombinant human angiotensin-converting enzyme 2 [rhACE2]). Data are expressed as adjusted median ± 95% credible interval (CrI). n* is number of subjects available for each measurement.
following dosing with GSK2586881. In contrast, Ang II levels in subjects receiving placebo remained elevated over the first 5 days and decreased thereafter. Plasma Ang 1–7 (Fig. 2b) and Ang 1–5 (Fig. 2c) levels increased rapidly and were sustained over the first 12 h following dosing with GSK2586881 and remained substantially elevated. Similarly, Ang 1–5 levels (a product of Ang 1–7 catabolism) also increased rapidly over the first 6 h and remained elevated over a time frame similar to that of Ang 1–7 (Fig. 2c). Plasma levels of Ang 1–7 and Ang 1–5 were unchanged over the same period in patients who received placebo.

Baseline plasma Ang II concentrations were higher in nonsurvivors than in survivors (Additional file 1: Figure S2a), consistent with literature reports suggesting a link between Ang II concentrations and outcome in ARDS [16, 17]. Although baseline concentrations were higher in patients with ARDS than previously reported for healthy subjects [25], overall Ang II levels were low (Table 1). Among patients in part B, 44% presented with concentrations < 10 pg/ml (within the normal range), and the majority of subjects recruited (~70%) had Ang II concentrations < 50 pg/ml (Additional file 1: Figure S2b).

Plasma renin levels were decreased in both groups at 72 h compared with baseline. Aldosterone levels were decreased in subjects receiving GSK2586881 at 72 h compared with placebo; however, the difference was not significant (data not shown).

**Other biomarkers**

Baseline serum interleukin (IL)-6 concentrations were substantially higher at baseline in the rhACE2 arm (763.6 pg/ml, 95% credible interval (CrI) 427.4–1364.4; vs 223.5 pg/ml, 95% CrI 80.1–623.6) (Fig. 3a). Following adjustment for baseline differences, there was an apparent treatment-related decrease in IL-6 concentrations in GSK2586881-treated patients compared with placebo after 24 h that did not reach statistical significance (posterior probability distribution of 0.5130–0.9254). The trend for lower IL-6 concentrations is supported by posterior probabilities of 0.92 and 0.88 that

![Fig. 3](image-url)
GSK2586881 reduced IL-6 levels at 48 h and 120 h, respectively (Fig. 3b).

Concentrations of surfactant protein D (SP-D) increased compared with baseline (257.7 ng/ml, 95% CrI 162.2–409.5) in subjects receiving GSK2586881, reaching a maximum at 48 h (494.7 ng/ml, 95% CrI 391.6–628.3) and then gradually decreasing (Fig. 3c). SP-D levels were significantly elevated (posterior probability > 0.95) in GSK2586881-treated subjects following dosing compared with placebo-treated subjects at 12, 24, 48, and 72 h (Fig. 3d), indicating strong evidence for a treatment-related effect.

In both groups, myeloperoxidase levels remained relatively constant for 48 h before decreasing, and there was a trend toward lower levels in placebo-treated subjects (posterior probabilities 0.93 at 24 h and 0.92 at 72 h). No significant difference was observed among treatment groups for other biomarkers, including C-X-C motif chemokine ligand 8, soluble tumor necrosis factor receptor 1, C-reactive protein, receptor for advanced glycation endproducts, Club cell protein-16, angiopoietin-2, von Willebrand factor, or plasminogen activator inhibitor 1. Tumor necrosis factor-α concentrations were below the level of assay quantification (23.5 pg/ml) for all samples in the GSK2586881-treated group.

**Clinical efficacy**

**Physiological and ventilatory endpoints**

There were no significant differences in PaO$_2$/FiO$_2$ over the dosing period in part B, and PaO$_2$/FiO$_2$ was not increased at the final time point (168 h postdose) in the rhACE2 group compared with placebo (rhACE2/placebo ratio 0.85, 95% CrI 0.62–1.1) (Fig. 4a). Similarly, there were no differences between treatment groups in oxygenation index or positive end-expiratory pressure [29]. The lack of effect on oxygenation was observed regardless of baseline Ang II levels (data not shown). There were no significant differences in either peak or plateau pressures between placebo and GSK2586881 over the 72 h of treatment; however, increases in both peak and plateau pressures in those subjects who had received GSK2586881 was evident following the end of treatment. The increase in peak pressures at 72 h was statistically significant (ratio 1.28, 95% CrI 1.059–1.514, posterior probability [ratio > 1] 0.9946) (Fig. 4b). Static compliance was lower in the GSK2586881-treated group than in the placebo group throughout the study, but it decreased more notably after 60 h (Fig. 4c). The ratio for static compliance at 72 h was 0.58 (95% CrI 0.303–1.308) with a posterior probability (ratio ≥ 1) of 0.0750, suggesting a statistically significant difference favoring placebo. It should be noted, however, that the analysis at 72 h for these parameters was based on 10 subjects (4 in placebo, 6 on GSK2586881) compared with 23 at baseline (13 and 10, respectively).

**Organ failure**

SOFA scores were higher in the GSK2586881-treated group at baseline, and when they could be computed, they were also higher at all postdose time points (Additional file 1: Table S6). Notably, there was a large proportion of missing data at day 7 because of clinical improvement, which limits the conclusions that can be drawn. Fluid balance was also assessed in patients at baseline and throughout the treatment period, with no significant differences noted between treatment groups across time points (data not shown).

**Discussion**

The primary objective of this study was to assess the safety of GSK2586881 in patients with ARDS, and the study also included measurements of inflammatory changes in oxygenation and static compliance. The results indicate that GSK2586881 has a statistically significant effect on certain biomarkers, such as SP-D, which is consistent with its purported mechanism of action as a soluble ACE2 receptor. However, the clinical efficacy endpoints, including PaO$_2$/FiO$_2$, did not show significant differences between the treatment and placebo groups, which may be due to the short duration of the study or other confounding factors. The lack of effect on oxygenation was observed regardless of baseline Ang II levels, and the study highlights the importance of further investigation into the role of ACE2 inhibition in the management of ARDS.
products were limited to the initial 30–GSK2586881 only in patients with elevated Ang II and, in
searchers in future studies could consider evaluating be driving disease in only a subgroup of patients. Re-
ARDS and raises the possibility that RAS activation may
activation within heterogeneous cohorts of patients with
31, 32]. This observation highlights the variability in RAS
prognostic significance in some patient populations [17,
to explore these PK/PD relationships.
1 concentrations over a longer duration may be more ef-
infusion, perhaps reflecting high turnover of the initial
Ang II substrate pool in the presence of high concentra-
infusion, and measured ACE2 activity (Additional file 1: Figure
S4). Whereas infusion of GSK2586881 resulted in a
mean decrease in Ang II, levels in some subjects
S4). Whereas infusion of GSK2586881 resulted in a
mean decrease in Ang II, levels in some subjects
remained higher than those reported in healthy volun-
ters [25]. Increases in Ang 1–7 and Ang 1–5 peptide
products were limited to the initial 30–60 minutes after infusion, perhaps reflecting high turnover of the initial
Ang II substrate pool in the presence of high concentra-
tions of rhACE2. This raises the possibility that continu-
ous infusions of GSK2586881 that achieve lower plasma
concentrations over a longer duration may be more ef-
effective as a result of more sustained production of Ang
1–7. Further dose regimen finding studies are required to
explore these PK/PD relationships.

It is notable that 71% of patients had baseline concen-
trations of Ang II < 50 pg/ml, a level suggested to be of
prognostic significance in some patient populations [17,
31, 32]. This observation highlights the variability in RAS
activation within heterogeneous cohorts of patients with
ARDS and raises the possibility that RAS activation may
be driving disease in only a subgroup of patients. Re-
searchers in future studies could consider evaluating
GSK2586881 only in patients with elevated Ang II and, in
light of findings in animals, could further explore the im-
 pact of RAS modulation on pulmonary hemodynamics
and markers of pulmonary vascular injury.

Treatment with GSK2586881 resulted in a reduction in
IL-6 concentrations, although this did not reach stat-
istical significance, owing to intersubject variability and
baseline imbalances. The elevations in SP-D were unex-
pected and raise a number of questions about
GSK2586881’s mechanism of action. SP-D is a large
collectin family protein, with expression usually restricted
to the lung [33, 34]. Its presence in serum has been
suggested to be an indicator of worsening alveolar cap-
illary permeability. However, SP-D is also an anti-
flammatory [33, 34] and antimicrobial protein [35];
thus, the observed increases could be reflective of in-
creased SP-D biosynthesis in the lung as a result of
GSK2586881 treatment. These data highlight a need for
further research on the potential mechanistic link
between ACE2 and SP-D biology.

Although difficult to assess because of study limitations,
it is possible that treatment with GSK2586881 worsened
respiratory mechanics, with the change in compliance and
ventilatory pressures possibly suggesting an increase in lung
stiffness [29, 36, 37]. Although most of the biomarkers
measured suggested no change or reduced disease activity
in GSK2586881-treated subjects, the increase in myeloper-
oxidase is difficult to explain on the basis of known ACE2
biology and previous effects in animals and humans, and it
could reflect lung neutrophil accumulation and the poten-
tial for altered respiratory mechanics. Some of the analyses
were impacted by missing data (e.g., subject withdrawal,
extubation, technical issues, early mortality); therefore, the
number of subjects supporting these comparisons was
small, significantly increasing the possibility of systematic
bias at later time points. There were baseline imbalances in
severity of illness (based on SOFA score and serum IL-6
and Ang II levels) and case mix between treatment groups.

The lack of improvement in oxygenation in patients
receiving GSK2586881 contrasts with effects reported in
large animal models of ARDS, where IV rhACE2 rapidly
improved arterial hypoxemia and pulmonary hemodynamics
[15, 38]. Although PaO2/FiO2 and other ventilatory parame-
ters are important in the diagnosis of ARDS and in de-
termining the severity of hypoxemia, they cannot be
standardized clinically to the same extent as in animal
studies, and they are influenced by numerous factors that
were not adequately controlled for in this trial. These issues
limit interpretation of the effects of GSK2586881 on oxy-
genation and ventilatory parameters.

**Conclusions**

Infusion of GSK2586881 resulted in the expected changes in
RAS biomarkers and were well-tolerated in subjects
with ARDS. However, GSK2586881 infusions did not
result in improvement in physiological or clinical measures of ARDS in this small study. Because the primary objective (preliminary safety, PK, and PD) was met at the interim analysis, and because statistical trial simulations of the interim data predicted with reasonable confidence that the outcome at trial completion ($n = 60$) would be similar to the interim outcome, continued recruitment was not justified, and the trial was terminated early. Further exploration of the effects of GSK2586881 in ARDS will need to be built on a better understanding of the role of RAS in ARDS pathophysiology in humans, as well as of the effects of rhACE2 on pulmonary physiology.

Additional files

- **Additional file 1**: Online Supplement to Pilot trial of ACE2 in ARDS. (DOCX 408 kb)
- **Additional file 2**: Ethics Committees and Institutional Review Boards. (DOCX 13 kb)

Abbreviations

ACE2: Angiotensin-converting enzyme 2; AE: Adverse event; ALI: Acute lung injury; Ang: Angiotensin; ARDS: Acute respiratory distress syndrome; AT1R: Angiotensin type 1 receptor; BMI: Body mass index; CONSORT: Consolidated Standards of Reporting Trials; CRI: Credible interval; D: Dose; DE: Deletion; IL: Interleukin; IV: Intravenous; LLOQ: Lower limit of quantitation; PaO$_2$/FiO$_2$: Ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; PD: Pharmacodynamics; PEEP: Positive end-expiratory pressure; PK: Pharmacokinetics; RAS: Renin-angiotensin system; rhACE2: Recombinant human angiotensin-converting enzyme 2; SAE: Serious adverse event; SP-D: Surfactant protein D; SOFA: Sequential Organ Failure Assessment

Acknowledgements

The authors thank the patients and their families, as well as the following principal investigators and study coordinators and their institutions for their contributions to the study:

**United States**: Kelli Brooks (Duke University Medical Center, Durham, NC), Peter Morris (Wake Forest University School of Medicine, Winston-Salem, NC), Richard Wunderink (Northwestern Memorial Hospital, Chicago, IL), Evert Eriksson (Medical University of South Carolina, Charleston, SC), Juan Duchesne (Tulane University School of Medicine, New Orleans, LA), Hayley Gershengorn (Albert Einstein College of Medicine, Bronx, NY), Robert Hyz (University of Michigan Medical Center, Ann Arbor, MI), Patrick Wright (Moses H. Cone Memorial Hospital, Greensboro, NC), Bharat Awarade (Thomas Jefferson University, Philadelphia, PA), Nathan Kessler (Oregon Health & Science University, Portland, OR), Katherine Markelz and Ana Campbell (University of Pennsylvania, Philadelphia, PA), Brian Morrissey (University of California, Davis School of Medicine, Sacramento, CA), Lori-Ann Kozlowski and Lesley De Souza (Baystate Medical Center, Springfield, MA).

**Singapore**: Francois Lellouche (Institut Universitaire de Cardiologie et de Pneumologie de Québec, Sainte-Foy, PQ), John Muscedere (Kingston General Hospital, Kingston, ON), Yoanna Skrobik (McGill University Health Centre, Montreal, QC), Mélissa Joseph (Charles LeMoyne Hospital, Greenfield Park, QC).

The authors also acknowledge the contributions of the following GSK employees in the United States, United Kingdom, and Canada: Sandi VanBurens, Alina Goetz, Amanda Baines, Hina Abbas, Ann Barella, Kitar Ubihi, Adam Hughes, Thomas Mencken, and Thomas Lee. The authors acknowledge the assistance of Gillan Groeger of Fishawack Communications for assistance in producing the figures (funded by GSK).

Funding

Funding for this study (NCT01597635) was provided by GlaxoSmithKline.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

All listed authors meet the criteria for authorship set forth by the International Committee of Medical Journal Editors, ALL, DAL, AIB, KH, WMP, TJW, SKS, and DAF were responsible for study design as well as data collection and analysis. AK, CB, BZ, TEA, JB, JD, RH, GP, JJR, and MT contributed to data acquisition. All authors contributed to data interpretation. AK and AL wrote the initial draft of the manuscript. All authors participated in review and revision of the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Authors’ information

Not applicable.

Ethics approval and consent to participate

After institutional review board approval was provided at each institution (available as part of Additional file 2), written informed consent was obtained from each patient or the patient’s legally authorized surrogate prior to conduct of study-specific procedures.

Consent for publication

Not applicable.

Competing interests

AK has received funding from GlaxoSmithKline, AstraZeneca, United Therapeutics, and Actelion Pharmaceuticals to conduct industry-sponsored research studies. TEA has received funding from GlaxoSmithKline to conduct industry-sponsored research studies. JDC has received institutional funding from GlaxoSmithKline and Bristol-Meyer Squibb to conduct investigator-initiated observational studies. RH has received funding from GlaxoSmithKline, Asahi Kasei Pharma, La Jolla Pharmaceutical, Eli Lilly, AstraZeneca, and Pfizer to conduct industry-sponsored research studies. KH, WMP, TJW, SKS, DAL, AIB, and ALL are employees of GSK and own shares in the company. The other authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Div. of Pulmonary & Critical Care Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA. 2. Riverside Methodist Hospital, Columbus, OH, USA. 3. School of Medicine, University of California, Davis, Sacramento, CA, USA. 4. St. Paul’s Hospital, Vancouver, BC, Canada. 5. Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 6. Nova Scotia Health Authority and Dalhousie University, Halifax, NS, Canada. 7. Charles LeMoyne Hospital, Sherbrooke University, Greenfield Park, QC, Canada. 8. Critical Care Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada. 9. Division of Pulmonary and Critical Care, Department of Medicine, Baystate Medical Center, Springfield, MA, USA.


Received: 13 March 2017 Accepted: 22 August 2017

Published online: 07 September 2017

References


Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit